Every oxycodone tablet or capsule contains one active pharmaceutical ingredient, oxycodone hydrochloride, along with a set of inactive ingredients called excipients that hold the tablet together, control how fast the drug dissolves, and give it a recognizable color and shape. The exact list of inactive ingredients varies depending on whether you have an immediate-release or extended-release product, whether it is a brand name or generic, and whether the formulation combines oxycodone with a second active drug like acetaminophen. But the active molecule at the center is always the same semi-synthetic opioid, and the excipients all serve specific pharmaceutical jobs worth understanding.
The Active Ingredient
Oxycodone hydrochloride is the pain-relieving compound in every oxycodone product. The “hydrochloride” part refers to the salt form of the molecule, meaning oxycodone has been paired with hydrochloric acid to make it more water-soluble and stable in a tablet. This salt form is standard across virtually all oral oxycodone products on the market.
Oxycodone itself is classified as a semi-synthetic opioid. It is not harvested directly from the opium poppy but is built in a laboratory starting from thebaine, a naturally occurring compound found in the poppy plant. Thebaine is converted through a series of chemical steps, including oxidation with hydrogen peroxide and selective hydrogenation, to produce the final oxycodone molecule.1ScienceDirect. Oxycodone The drug has been in clinical use since 1917, originally as an injectable for acute postoperative pain and later in oral combination products.2ScienceDirect. Oxycodone
When you swallow a tablet, the oxycodone hydrochloride dissolves and enters your bloodstream, where it binds to opioid receptors in the brain and spinal cord. It acts as an agonist on mu, kappa, and delta opioid receptors, triggering a chain of events inside nerve cells that reduces the transmission of pain signals.3PubMed. Oxycodone: a pharmacological and clinical review The mu-opioid receptor is the primary target responsible for both pain relief and most of oxycodone’s side effects, including sedation, respiratory depression, and the potential for dependence.
How Your Body Processes Oxycodone
Once absorbed, oxycodone is broken down mainly by two liver enzymes, CYP3A4 and CYP2D6, with only a small fraction leaving the body unchanged in urine. One of the metabolites produced by CYP2D6, called oxymorphone, binds to the mu-opioid receptor roughly 40 to 60 times more strongly than oxycodone itself.4European Journal of Pharmaceutical Sciences. Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation This matters because people have different genetic versions of CYP2D6. Some people are “ultra-rapid metabolizers” who convert oxycodone to oxymorphone faster than average, which can intensify effects and side effects. Others are “poor metabolizers” who produce very little oxymorphone. Your genetic profile for this enzyme is one reason the same dose can feel noticeably different from one person to the next.
The salt form also affects absorption. When oxycodone hydrochloride is tested at different pH levels, its absorption through mucous membranes changes significantly. In one study comparing sublingual (under-the-tongue) delivery, the average bioavailability was about 45% at an acidic pH and about 70% at a more alkaline pH.5PubMed. Effect of pH on sublingual absorption of oxycodone hydrochloride This is not something that affects you when swallowing a standard tablet, since the stomach and intestines handle dissolution, but it illustrates why the chemical form of the active ingredient is carefully chosen for its intended route.
Immediate-Release Versus Extended-Release Formulations
The inactive ingredients in an oxycodone product depend heavily on whether it is designed for immediate release or extended release, and the difference is more than just how fast you feel the effect. These two formulation types use fundamentally different excipient strategies.
Immediate-release oxycodone dissolves quickly in the stomach and is absorbed rapidly. The inactive ingredients in these products are relatively simple: fillers to give the tablet bulk, binders to hold the powder together during compression, a lubricant so the tablet does not stick to manufacturing equipment, and sometimes a coating for appearance or taste masking.
Extended-release (also called controlled-release) tablets, on the other hand, are engineered to deliver oxycodone over a much longer window, typically around 12 hours. The pharmacokinetic profile of a controlled-release oxycodone tablet shows two distinct absorption phases: a rapid initial phase with a half-life of absorption around 37 minutes that accounts for roughly 38% of the dose, followed by a slow phase with a half-life of about 6.2 hours that accounts for the remaining 62%.6PubMed Central. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone Getting this two-phase profile right requires a matrix of excipients that control how water penetrates the tablet and how fast the drug dissolves out of it.
Common Inactive Ingredients and What They Do
While the specific excipients differ by manufacturer and product, most oxycodone tablets share a few categories of inactive ingredients. Here is what you are likely to find listed on a product label and why each is there.
Fillers and Binders
Oxycodone is a potent drug, meaning the actual weight of active ingredient per tablet is tiny, sometimes just a few milligrams. Without a filler, the tablet would be too small to handle. Common fillers include lactose, microcrystalline cellulose, and starch. These substances add bulk so the tablet is a manageable size. Binders like povidone or hydroxypropyl cellulose help the powder particles stick together during manufacturing so the tablet does not crumble. The ratio of excipient weight to drug weight matters: when extended-release oxycodone tablets are physically manipulated (crushed or milled), the initial excipient-to-drug ratio affects how much oxycodone is lost during the process, though it does not significantly change how the remaining drug dissolves.7Pharmaceutical Research. Preferential Oxycodone Loss of Physically Manipulated Abuse Deterrent Oxycodone HCl Extended Release Tablets Prepared for Nasal Insufflation Studies
Lubricants
Magnesium stearate is the most widely used lubricant in pharmaceutical tablet manufacturing.8PubMed Central. Effect of magnesium stearate concentration on dissolution properties of ranitidine hydrochloride coated tablets Its job is to reduce friction between the tablet and the metal surfaces of the compression equipment, preventing the tablet from sticking to the die or punch during production.9An-Najat. Review: Peran Zat Pelicin dalam Meningkatkan Efisiensi Proses Pembutan Sediaan Tablet Oral Without a lubricant, tablets can crack, chip, or jam equipment. The amount used is usually small, typically around 0.5% to 1% of the total tablet weight, because too much can slow down how fast the tablet dissolves.
Film Coatings and Colorants
Most oxycodone tablets have a thin film coating, often made from hypromellose (hydroxypropyl methylcellulose), which gives the tablet a smooth surface for easier swallowing. Titanium dioxide is frequently added to this coating. It serves a dual purpose: it disperses visible and UV light to protect the active ingredient from degradation, and it provides a uniform white or opaque base color that helps with product identification and batch-to-batch consistency.10Journal of Pharmaceutical Sciences. The Role of Titanium Dioxide (E171) and the Requirements for Replacement Materials in Oral Solid Dosage Forms Color consistency also plays a role in anti-counterfeiting efforts, since a tablet that looks slightly off from its expected shade raises a red flag for pharmacists and patients.
However, titanium dioxide is not purely beneficial to the coating. Research has shown that while it protects the active ingredient from light, it can actually promote the breakdown of the coating polymer itself over time when exposed to light.11PubMed. Changes in Tablet Color Due to Light Irradiation: Photodegradation of the Coating Polymer, Hypromellose, by Titanium Dioxide This is why proper storage conditions (closed containers, away from light) matter even for tablets that appear to be well protected by their coating.
Various iron oxide pigments and other FDA-approved colorants are added to differentiate dosage strengths. The color coding system is not decorative. A 5 mg oxycodone tablet looks different from a 10 mg or 20 mg tablet specifically to reduce dosing errors.
Controlled-Release Matrix Materials
Extended-release oxycodone tablets rely on a polymer matrix, most commonly polyethylene oxide, to control how the drug is released over time. Polyethylene oxide swells when it contacts water, forming a gel barrier around the tablet core that gradually erodes, allowing oxycodone to seep out at a controlled rate. Most abuse-deterrent opioid products on the market use polyethylene oxide as a key ingredient.12Pharmaceutical Development and Technology. A review on abuse-deterrent formulations: formulation technology and regulatory stands in approval process This polymer also contributes to the abuse-deterrent properties of the tablet, because when someone tries to crush or dissolve the tablet for misuse, the polyethylene oxide gums up into a sticky mass that is difficult to inject or snort.
When Oxycodone Is Combined with Other Active Ingredients
Some of the most widely prescribed oxycodone products are not oxycodone alone. Combination formulations pair oxycodone with acetaminophen (paracetamol), sold under brand names like Percocet and numerous generics. In these products, your tablet contains two active ingredients instead of one.
The rationale for combining them is pharmacological synergy. Acetaminophen works through a central analgesic mechanism that is distinct from oxycodone’s opioid receptor activity, so the two drugs relieve pain through different pathways at the same time. This synergy allows lower doses of each individual drug to be used, which reduces the severity of opioid-related side effects while still providing effective pain relief for moderate-to-severe pain.13PubMed. Oxycodone/paracetamol: a low-dose synergic combination useful in different types of pain The opioid-sparing effect is one of the main selling points of combination products.
If you are taking a combination product, the acetaminophen content is important to track. Acetaminophen has a well-known ceiling for liver safety, and taking additional acetaminophen-containing products (cold medicines, other pain relievers) on top of your oxycodone-acetaminophen tablet can push you past that ceiling without you realizing it. This is a practical concern that pure oxycodone products do not share.
Abuse-Deterrent Formulation Technology
Since the mid-2000s, pharmaceutical companies have invested heavily in abuse-deterrent formulations (ADFs) for extended-release oxycodone. These are not separate ingredients in the way a filler or lubricant is. Instead, they are engineering strategies built into the tablet’s excipient design to make it harder to misuse the product by crushing, dissolving, or extracting the oxycodone.
The most common approach, used in reformulated OxyContin and similar products, relies on the polyethylene oxide matrix described earlier. When the tablet is crushed, the polymer resists breaking into a fine powder and instead deforms into a flattened waxy mass. When someone tries to dissolve it in water or alcohol to draw it into a syringe, the polymer forms a thick gel that cannot be easily filtered or injected. Different manufacturers have pursued various additional strategies, including chemical antagonists (adding naloxone or naltrexone that becomes active only if the tablet is tampered with), aversive agents that cause unpleasant effects if the drug is taken in ways other than swallowing, and physical barriers beyond polyethylene oxide.14PubMed Central. Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics
One limitation worth knowing: polyethylene oxide degrades at high temperatures.12Pharmaceutical Development and Technology. A review on abuse-deterrent formulations: formulation technology and regulatory stands in approval process This means storage conditions are more than a suggestion for these products. Leaving extended-release oxycodone in a hot car or near a heat source could compromise the matrix that controls its release rate, potentially changing how the drug enters your system.
Can Inactive Ingredients Cause Problems?
Most people swallow their oxycodone and never give a thought to the inactive ingredients, and for the majority of patients this is perfectly fine. But excipients are not biologically inert for everyone. A broad analysis of more than 42,000 oral medications found that most commonly prescribed drugs contain at least one inactive ingredient that has been described in the medical literature as capable of causing allergic symptoms after oral exposure, with more than three dozen such ingredients identified.15Research Journal of Pharmacy and Technology. Pharmacovigilance implications of some inactive pharmaceutical ingredients
For oxycodone products specifically, the most common culprits are lactose and certain dyes. Lactose, used as a filler in many immediate-release tablets, can cause gastrointestinal symptoms in people with lactose intolerance, though the amount in a single tablet is usually quite small compared to what is in a glass of milk. Dyes like FD&C Yellow No. 6 or Red No. 40 have been flagged in rare case reports of hypersensitivity reactions. Titanium dioxide has drawn regulatory scrutiny in Europe (where it has been banned as a food additive, though pharmaceutical use is still permitted under an exemption), though evidence for harm at the doses found in tablet coatings remains limited.
If you have a known allergy or sensitivity to a specific excipient, switching between brand-name and generic versions of oxycodone, or even between different generics, can make a difference because the inactive ingredient lists are not identical across manufacturers. Pharmacists can help identify which products use which excipients, and some manufacturers publish their full ingredient lists on the FDA’s Drugs@FDA database.
Why Different Oxycodone Products Look and Feel Different
If you have ever noticed that your oxycodone tablets changed color, size, or shape after a pharmacy switch, the reason is almost always a change in inactive ingredients rather than the active drug. Generic manufacturers choose their own excipient profiles within FDA guidelines. One company’s 10 mg immediate-release oxycodone tablet might be a small white round pill, while another’s is a slightly larger pink oval. The oxycodone hydrochloride inside is held to the same bioequivalence standard, meaning it must deliver the drug into your bloodstream at essentially the same rate and extent as the reference product.
That said, the excipient differences can occasionally produce subtle differences in how a tablet feels to patients, particularly in the gastrointestinal tract. A tablet with more lactose filler might cause mild bloating in a sensitive individual. A different coating polymer might alter the initial taste if a tablet starts dissolving before it is fully swallowed. These differences are real, even if they are not differences in the active ingredient itself, and they help explain why some patients report that one manufacturer’s version “works differently” from another’s, even when the oxycodone content is identical.
Extended-release products add another layer of complexity. Because the controlled-release mechanism depends entirely on the excipient matrix, the specific polymer system, tablet geometry, and coating design all influence the drug’s release curve. Generic extended-release oxycodone products must demonstrate that their release profile matches the reference product within acceptable bounds, but the excipients used to achieve that match can be entirely different from the brand-name version. For this reason, the FDA evaluates abuse-deterrent claims separately for each product. A generic extended-release oxycodone that is bioequivalent does not automatically receive the same abuse-deterrent labeling unless it can independently demonstrate those properties.